Sign in
DVAX Stock Price, Chart, Stats & News
Dynavax Technologies Corporation
Save
Dynavax Technologies Corporation (DVAX) does not currently pay a dividend.
1.82B
Market cap
–
Current P/E
29.24x
Forward P/E
DVAX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 83.17% |
Operating margin | 3.16% |
Pretax margin | -12.29% |
Net margin | -13.13% |
Effective tax rate | -6.87% |
ROA | -4.59% |
ROE | -8.05% |
D/E | 0.53x |
Interest coverage ratio | 1.63x |
DVAX valuation
P/E | – |
P/S | 5.51x |
P/B | 3.40x |
P/CF | 20.06x |
P/FCF | 22.60x |
P/OCF | 20.06x |
PEG | -1.76x |
EV multiple | -66.10x |
About
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U. S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus.
Similar securities
Based on sector and market capitalization
Report issue